Onconetix FY2025 net loss narrows 76% to $14.03 million as revenue falls 68% to $0.82 million

Reuters

Mar 14

Onconetix FY2025 net loss narrows 76% to $14.03 million as revenue falls 68% to $0.82 million

Onconetix reported FY 2025 revenue of USD 0.82 million, down 68%, and cost of revenue of USD 0.18 million, down 88%. FY 2025 net loss narrowed 76% to USD 14.03 million, while loss from operations improved 68% to USD 17.86 million. FY 2025 selling, general and administrative expense fell 37% to USD 7.04 million, driven by lower payroll costs from headcount reductions and lower benefit costs following settlement of a defined benefit plan. The company recorded FY 2025 impairment of goodwill of USD 11.51 million, down 64%. Onconetix said it abandoned commercialization of ENTADFI and is focusing on commercializing Proclarix, while noting cash of USD 5.2 million at year-end and that it expects growing Proclarix revenues in 2026 and beyond.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-027725), on March 13, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2619445148"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619445148\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619445148?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-14 04:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619445148","market":"fut","top_or_hot":-1,"title":"Onconetix FY2025 net loss narrows 76% to $14.03 million as revenue falls 68% to $0.82 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Onconetix FY2025 net loss narrows 76% to $14.03 million as revenue falls 68% to $0.82 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Onconetix reported FY 2025 revenue of USD 0.82 million, down 68%, and cost of revenue of USD 0.18 million, down 88%. FY 2025 net loss narrowed 76% to USD 14.03 million, while loss from operations improved 68% to USD 17.86 million. FY 2025 selling, general and administrative expense fell 37% to USD 7.04 million, driven by lower payroll costs from headcount reductions and lower benefit costs following settlement of a defined benefit plan. The company recorded FY 2025 impairment of goodwill of USD 11.51 million, down 64%. Onconetix said it abandoned commercialization of ENTADFI and is focusing on commercializing Proclarix, while noting cash of USD 5.2 million at year-end and that it expects growing Proclarix revenues in 2026 and beyond.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ONCO\">Onconetix Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-027725), on March 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Onconetix FY2025 net loss narrows 76% to $14.03 million as revenue falls 68% to $0.82 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOnconetix FY2025 net loss narrows 76% to $14.03 million as revenue falls 68% to $0.82 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-14 04:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Onconetix FY2025 net loss narrows 76% to $14.03 million as revenue falls 68% to $0.82 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Onconetix reported FY 2025 revenue of USD 0.82 million, down 68%, and cost of revenue of USD 0.18 million, down 88%. FY 2025 net loss narrowed 76% to USD 14.03 million, while loss from operations improved 68% to USD 17.86 million. FY 2025 selling, general and administrative expense fell 37% to USD 7.04 million, driven by lower payroll costs from headcount reductions and lower benefit costs following settlement of a defined benefit plan. The company recorded FY 2025 impairment of goodwill of USD 11.51 million, down 64%. Onconetix said it abandoned commercialization of ENTADFI and is focusing on commercializing Proclarix, while noting cash of USD 5.2 million at year-end and that it expects growing Proclarix revenues in 2026 and beyond.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ONCO\">Onconetix Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-027725), on March 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL3HFbHB:1","article_id":"2619445148","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619445148","pubTimestamp":1773434926,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Onconetix reported FY 2025 revenue of USD 0.82 million, down 68%, and cost of revenue of USD 0.18 million, down 88%. FY 2025 net loss narrowed 76% to USD 14.03 million, while loss from operations improved 68% to USD 17.86 million. FY 2025 selling, general and administrative expense fell 37% to USD 7.04 million, driven by lower payroll costs from headcount reductions and lower benefit costs following settlement of a defined benefit plan. The company recorded FY 2025 impairment of goodwill of USD 11.51 million, down 64%. Onconetix said it abandoned commercialization of ENTADFI and is focusing on commercializing Proclarix, while noting cash of USD 5.2 million at year-end and that it expects growing Proclarix revenues in 2026 and beyond.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ONCO":"Onconetix Inc."},"translate_title":"Onconetix 2025财年净亏损收窄76%至1,403万美元，收入下降68%至82万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONCO":0.9},"content_text":"Onconetix FY2025 net loss narrows 76% to $14.03 million as revenue falls 68% to $0.82 million\n    \n\n        Onconetix reported FY 2025 revenue of USD 0.82 million, down 68%, and cost of revenue of USD 0.18 million, down 88%. FY 2025 net loss narrowed 76% to USD 14.03 million, while loss from operations improved 68% to USD 17.86 million. FY 2025 selling, general and administrative expense fell 37% to USD 7.04 million, driven by lower payroll costs from headcount reductions and lower benefit costs following settlement of a defined benefit plan. The company recorded FY 2025 impairment of goodwill of USD 11.51 million, down 64%. Onconetix said it abandoned commercialization of ENTADFI and is focusing on commercializing Proclarix, while noting cash of USD 5.2 million at year-end and that it expects growing Proclarix revenues in 2026 and beyond.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-027725), on March 13, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}